Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma

Susan J. Knox, Michael L. Goris, Kirk Trisler, Robert Negrin, Thomas Davis, Tina Marie Liles, Antonio Grillo-López, Paul Chinn, Chet Varns, Shou Cheng Ning, Sherry Fowler, Nimisha Deb, Mark Becker, Carol Marquez, Ronald Levy

Research output: Contribution to journalArticle

343 Citations (Scopus)

Abstract

A Phase I/II dose escalation study of 90Y-murine anti-CD20 monoclonal antibody (mAb) in patients with recurrent B-cell lymphoma was performed. The primary objectives of the study were: (a) to determine the effect of the preinfusion of unlabeled anti-CD20 mAb on the biodistribution of 111In-anti-CD20 mAb; (b) to determine the maximal tolerated dose of 90Y-anti-CD20 mAb that does not require bone marrow transplantation; and (c) to evaluate the safety and antitumor effect of 90Y-anti-CD20 mAb in patients with recurrent B-cell lymphoma. Eighteen patients with relapsed low- or intermediate-grade non-Hodgkin's lymphoma were treated. Biodistribution studies with 111In-anti-CD20 mAb were performed prior to therapy. Groups of three or four patients were treated at dose levels of ~ 13.5, 20, 30, 40, and 50 mCi 90Y-anti-CD20 mAb. Three patients were retreated at the 40-mCi dose level. The use of unlabeled antibody affected the biodistribution favorably. Nonhematological toxicity was minimal. The only significant toxicity was myelosuppression. The overall response rate following a single dose of 90Y-anti-CD20 mAb therapy was 72%, with six complete responses and seven partial responses and freedom from progression of 3-29+ months following treatment, Radioimmunotherapy with ≤50 mCi 90Y-anti-CD20 mAb resulted in minimal nonhematological toxicity and durable clinical responses in patients with recurrent B cell lymphoma. Doses of ≤40 mCi 90Y-anti-CD20 mAb were not myeloablative.

Original languageEnglish (US)
Pages (from-to)457-470
Number of pages14
JournalClinical Cancer Research
Volume2
Issue number3
StatePublished - Mar 1996
Externally publishedYes

Fingerprint

Yttrium
B-Cell Lymphoma
Monoclonal Antibodies
Therapeutics
Non-Hodgkin's Lymphoma
Radioimmunotherapy
Maximum Tolerated Dose
Bone Marrow Transplantation
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., Liles, T. M., ... Levy, R. (1996). Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Research, 2(3), 457-470.

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. / Knox, Susan J.; Goris, Michael L.; Trisler, Kirk; Negrin, Robert; Davis, Thomas; Liles, Tina Marie; Grillo-López, Antonio; Chinn, Paul; Varns, Chet; Ning, Shou Cheng; Fowler, Sherry; Deb, Nimisha; Becker, Mark; Marquez, Carol; Levy, Ronald.

In: Clinical Cancer Research, Vol. 2, No. 3, 03.1996, p. 457-470.

Research output: Contribution to journalArticle

Knox, SJ, Goris, ML, Trisler, K, Negrin, R, Davis, T, Liles, TM, Grillo-López, A, Chinn, P, Varns, C, Ning, SC, Fowler, S, Deb, N, Becker, M, Marquez, C & Levy, R 1996, 'Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma', Clinical Cancer Research, vol. 2, no. 3, pp. 457-470.
Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Research. 1996 Mar;2(3):457-470.
Knox, Susan J. ; Goris, Michael L. ; Trisler, Kirk ; Negrin, Robert ; Davis, Thomas ; Liles, Tina Marie ; Grillo-López, Antonio ; Chinn, Paul ; Varns, Chet ; Ning, Shou Cheng ; Fowler, Sherry ; Deb, Nimisha ; Becker, Mark ; Marquez, Carol ; Levy, Ronald. / Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. In: Clinical Cancer Research. 1996 ; Vol. 2, No. 3. pp. 457-470.
@article{987cf5a3866a4445977b20248658a691,
title = "Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma",
abstract = "A Phase I/II dose escalation study of 90Y-murine anti-CD20 monoclonal antibody (mAb) in patients with recurrent B-cell lymphoma was performed. The primary objectives of the study were: (a) to determine the effect of the preinfusion of unlabeled anti-CD20 mAb on the biodistribution of 111In-anti-CD20 mAb; (b) to determine the maximal tolerated dose of 90Y-anti-CD20 mAb that does not require bone marrow transplantation; and (c) to evaluate the safety and antitumor effect of 90Y-anti-CD20 mAb in patients with recurrent B-cell lymphoma. Eighteen patients with relapsed low- or intermediate-grade non-Hodgkin's lymphoma were treated. Biodistribution studies with 111In-anti-CD20 mAb were performed prior to therapy. Groups of three or four patients were treated at dose levels of ~ 13.5, 20, 30, 40, and 50 mCi 90Y-anti-CD20 mAb. Three patients were retreated at the 40-mCi dose level. The use of unlabeled antibody affected the biodistribution favorably. Nonhematological toxicity was minimal. The only significant toxicity was myelosuppression. The overall response rate following a single dose of 90Y-anti-CD20 mAb therapy was 72{\%}, with six complete responses and seven partial responses and freedom from progression of 3-29+ months following treatment, Radioimmunotherapy with ≤50 mCi 90Y-anti-CD20 mAb resulted in minimal nonhematological toxicity and durable clinical responses in patients with recurrent B cell lymphoma. Doses of ≤40 mCi 90Y-anti-CD20 mAb were not myeloablative.",
author = "Knox, {Susan J.} and Goris, {Michael L.} and Kirk Trisler and Robert Negrin and Thomas Davis and Liles, {Tina Marie} and Antonio Grillo-L{\'o}pez and Paul Chinn and Chet Varns and Ning, {Shou Cheng} and Sherry Fowler and Nimisha Deb and Mark Becker and Carol Marquez and Ronald Levy",
year = "1996",
month = "3",
language = "English (US)",
volume = "2",
pages = "457--470",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma

AU - Knox, Susan J.

AU - Goris, Michael L.

AU - Trisler, Kirk

AU - Negrin, Robert

AU - Davis, Thomas

AU - Liles, Tina Marie

AU - Grillo-López, Antonio

AU - Chinn, Paul

AU - Varns, Chet

AU - Ning, Shou Cheng

AU - Fowler, Sherry

AU - Deb, Nimisha

AU - Becker, Mark

AU - Marquez, Carol

AU - Levy, Ronald

PY - 1996/3

Y1 - 1996/3

N2 - A Phase I/II dose escalation study of 90Y-murine anti-CD20 monoclonal antibody (mAb) in patients with recurrent B-cell lymphoma was performed. The primary objectives of the study were: (a) to determine the effect of the preinfusion of unlabeled anti-CD20 mAb on the biodistribution of 111In-anti-CD20 mAb; (b) to determine the maximal tolerated dose of 90Y-anti-CD20 mAb that does not require bone marrow transplantation; and (c) to evaluate the safety and antitumor effect of 90Y-anti-CD20 mAb in patients with recurrent B-cell lymphoma. Eighteen patients with relapsed low- or intermediate-grade non-Hodgkin's lymphoma were treated. Biodistribution studies with 111In-anti-CD20 mAb were performed prior to therapy. Groups of three or four patients were treated at dose levels of ~ 13.5, 20, 30, 40, and 50 mCi 90Y-anti-CD20 mAb. Three patients were retreated at the 40-mCi dose level. The use of unlabeled antibody affected the biodistribution favorably. Nonhematological toxicity was minimal. The only significant toxicity was myelosuppression. The overall response rate following a single dose of 90Y-anti-CD20 mAb therapy was 72%, with six complete responses and seven partial responses and freedom from progression of 3-29+ months following treatment, Radioimmunotherapy with ≤50 mCi 90Y-anti-CD20 mAb resulted in minimal nonhematological toxicity and durable clinical responses in patients with recurrent B cell lymphoma. Doses of ≤40 mCi 90Y-anti-CD20 mAb were not myeloablative.

AB - A Phase I/II dose escalation study of 90Y-murine anti-CD20 monoclonal antibody (mAb) in patients with recurrent B-cell lymphoma was performed. The primary objectives of the study were: (a) to determine the effect of the preinfusion of unlabeled anti-CD20 mAb on the biodistribution of 111In-anti-CD20 mAb; (b) to determine the maximal tolerated dose of 90Y-anti-CD20 mAb that does not require bone marrow transplantation; and (c) to evaluate the safety and antitumor effect of 90Y-anti-CD20 mAb in patients with recurrent B-cell lymphoma. Eighteen patients with relapsed low- or intermediate-grade non-Hodgkin's lymphoma were treated. Biodistribution studies with 111In-anti-CD20 mAb were performed prior to therapy. Groups of three or four patients were treated at dose levels of ~ 13.5, 20, 30, 40, and 50 mCi 90Y-anti-CD20 mAb. Three patients were retreated at the 40-mCi dose level. The use of unlabeled antibody affected the biodistribution favorably. Nonhematological toxicity was minimal. The only significant toxicity was myelosuppression. The overall response rate following a single dose of 90Y-anti-CD20 mAb therapy was 72%, with six complete responses and seven partial responses and freedom from progression of 3-29+ months following treatment, Radioimmunotherapy with ≤50 mCi 90Y-anti-CD20 mAb resulted in minimal nonhematological toxicity and durable clinical responses in patients with recurrent B cell lymphoma. Doses of ≤40 mCi 90Y-anti-CD20 mAb were not myeloablative.

UR - http://www.scopus.com/inward/record.url?scp=9044254117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044254117&partnerID=8YFLogxK

M3 - Article

C2 - 9816191

AN - SCOPUS:9044254117

VL - 2

SP - 457

EP - 470

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -